. "Faber, Edgar" . "Urb\u00E1nkov\u00E1, Helena" . . . "11"^^ . "1" . . . "Holzerov\u00E1, Milena" . . "Cancer Genetics and Cytogenetics" . "Veselovsk\u00E1, Jitka" . "Ro\u017Emanov\u00E1, \u0160\u00E1rka" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . "191" . "Reported here are 72 previously treated Philadelphia chromosome?positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. The most frequent additional changes were deletions on the der(9q) (8 of 23), trisomy 8 (3 of 23), and an extra copy of the Ph chromosome (2 of 23). Five patients had a complex karyotype. At the latest follow-up, 49 of the 72 patients (68%) were alive, including 15 of the 23 patients with additional CAs (65%). Median follow-up was 6.6 years; median duration of IM treatment was 4.4 years. In all, 35 of the 49 patients with Ph only (71%) and 10 of the 23 patients with additional CAs (43%) achieved complete cytogenetic response. All patients with deletion on der(9q) achieved complete cytogenetic response. There was no statistically significant difference in the overall survival of pati"@en . . "0165-4608" . . "V\u00FDsledky l\u00E9\u010Dby imatinibem u 72 p\u0159edl\u00E9\u010Den\u00FDch Ph positivn\u00EDch CML pacient\u016F s a bez p\u0159\u00EDdatn\u00FDch chromosomov\u00FDch zm\u011Bn : v\u00FDsledky jednoho centra" . "Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results"@en . "V\u00FDsledky l\u00E9\u010Dby imatinibem u 72 p\u0159edl\u00E9\u010Den\u00FDch Ph positivn\u00EDch CML pacient\u016F s a bez p\u0159\u00EDdatn\u00FDch chromosomov\u00FDch zm\u011Bn : v\u00FDsledky jednoho centra" . . "Mu\u017E\u00EDk, Jan" . "RIV/61989592:15110/09:00009643!RIV10-MSM-15110___" . "V\u00FDsledky l\u00E9\u010Dby imatinibem u 72 p\u0159edl\u00E9\u010Den\u00FDch Ph positivn\u00EDch CML pacient\u016F s a bez p\u0159\u00EDdatn\u00FDch chromosomov\u00FDch zm\u011Bn : v\u00FDsledky jednoho centra"@cs . "Voglov\u00E1, Jaroslava" . "P(NC7490), P(NS9949), Z(MSM6198959205)" . . . "[6E4C5E6B845C]" . "Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results"@en . . . . "Chronic myeloid leukemia (CML); Imatinib; Ph chromozome"@en . "Indr\u00E1k, Karel" . "350495" . "9"^^ . . . "P\u0159edstavujeme soubor 72 p\u0159edl\u00E9\u010Den\u00FDch Ph pozitivn\u00EDch (Ph+) nemocn\u00FDch s CML l\u00E9\u010Den\u00FDch imatinibem (IM), s d\u016Frazem na pacienty s p\u0159\u00EDdatn\u00FDmi chromosomov\u00FDmi zm\u011Bnami (CAs). Na po\u010D\u00E1tku l\u00E9\u010Dby IM byl u 49 nemocn\u00FDch (68 %) prok\u00E1z\u00E1n v karyotypu pouze Ph chromosom, 23 nemocn\u00FDch (32 %) m\u011Blo krom\u011B Ph chromosomu je\u0161t\u011B jednu nebo v\u00EDce p\u0159\u00EDdatn\u00FDch CAs. Nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00EDdatnou chromosomovou zm\u011Bnou byla interstici\u00E1ln\u00ED delece 9q (8 z 23), trisomie chromosomu 8 (3 z 23) a dal\u0161\u00ED nadpo\u010Detn\u00FD Ph chromosom (2 z 23). P\u011Bt nemocn\u00FDch m\u011Blo komplexn\u00ED p\u0159estavby karyotypu. Podle posledn\u00EDho sledov\u00E1n\u00ED 49 (68 %) z 72 nemocn\u00FDch \u017Eije, v\u010Detn\u011B 15 z 23 nemocn\u00FDch s p\u0159\u00EDdatn\u00FDmi zm\u011Bnami (65 %). Medi\u00E1n sledov\u00E1n\u00ED byl 6,6 roku; medi\u00E1n l\u00E9\u010Dby IM byl 4,4 roku. 35 z 49 nemocn\u00FDch s Ph chromosomem (71 %) a 10 z 23 nemocn\u00FDch s p\u0159\u00EDdatn\u00FDmi zm\u011Bnami (43 %) dos\u00E1hli kompletn\u00ED cytogenetick\u00E9 odpov\u011Bdi. V\u0161ichni nemocn\u00ED s delec\u00ED 9q dos\u00E1hli kompletn\u00ED cytogenetick\u00E9 odpov\u011Bdi. Nen\u00ED statisticky v\u00FDznamn\u00FD rozd\u00EDl v celkov\u00E9m p\u0159e\u017Eit\u00ED nemocn\u00FDch s p\u0159\u00EDdatn\u00FDmi chromosomov\u00FDmi zm\u011Bnami" . "V\u00FDsledky l\u00E9\u010Dby imatinibem u 72 p\u0159edl\u00E9\u010Den\u00FDch Ph positivn\u00EDch CML pacient\u016F s a bez p\u0159\u00EDdatn\u00FDch chromosomov\u00FDch zm\u011Bn : v\u00FDsledky jednoho centra"@cs . "RIV/61989592:15110/09:00009643" . . . "Chroust, Karel" . . "Jaro\u0161ov\u00E1, Marie" . "15110" . . . . "P\u0159edstavujeme soubor 72 p\u0159edl\u00E9\u010Den\u00FDch Ph pozitivn\u00EDch (Ph+) nemocn\u00FDch s CML l\u00E9\u010Den\u00FDch imatinibem (IM), s d\u016Frazem na pacienty s p\u0159\u00EDdatn\u00FDmi chromosomov\u00FDmi zm\u011Bnami (CAs). Na po\u010D\u00E1tku l\u00E9\u010Dby IM byl u 49 nemocn\u00FDch (68 %) prok\u00E1z\u00E1n v karyotypu pouze Ph chromosom, 23 nemocn\u00FDch (32 %) m\u011Blo krom\u011B Ph chromosomu je\u0161t\u011B jednu nebo v\u00EDce p\u0159\u00EDdatn\u00FDch CAs. Nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00EDdatnou chromosomovou zm\u011Bnou byla interstici\u00E1ln\u00ED delece 9q (8 z 23), trisomie chromosomu 8 (3 z 23) a dal\u0161\u00ED nadpo\u010Detn\u00FD Ph chromosom (2 z 23). P\u011Bt nemocn\u00FDch m\u011Blo komplexn\u00ED p\u0159estavby karyotypu. Podle posledn\u00EDho sledov\u00E1n\u00ED 49 (68 %) z 72 nemocn\u00FDch \u017Eije, v\u010Detn\u011B 15 z 23 nemocn\u00FDch s p\u0159\u00EDdatn\u00FDmi zm\u011Bnami (65 %). Medi\u00E1n sledov\u00E1n\u00ED byl 6,6 roku; medi\u00E1n l\u00E9\u010Dby IM byl 4,4 roku. 35 z 49 nemocn\u00FDch s Ph chromosomem (71 %) a 10 z 23 nemocn\u00FDch s p\u0159\u00EDdatn\u00FDmi zm\u011Bnami (43 %) dos\u00E1hli kompletn\u00ED cytogenetick\u00E9 odpov\u011Bdi. V\u0161ichni nemocn\u00ED s delec\u00ED 9q dos\u00E1hli kompletn\u00ED cytogenetick\u00E9 odpov\u011Bdi. Nen\u00ED statisticky v\u00FDznamn\u00FD rozd\u00EDl v celkov\u00E9m p\u0159e\u017Eit\u00ED nemocn\u00FDch s p\u0159\u00EDdatn\u00FDmi chromosomov\u00FDmi zm\u011Bnami"@cs . . "Balc\u00E1rkov\u00E1, Jana" . "7"^^ .